Jegg Metchem senior analyst of BAC said that PFE has a lot of other things in their pipeline. They could have a !00 billion in revenue over the next four years. He believes they will be looking to bolt on acquisitions to boost their pipeline. He feels that PFE is better positioned going forward than MRNA because MRNA has to prove its pipeline. He believes countries will stock pile PFE's oral treatment to guard against flare-ups. He also said the oral is far more profitable because they don't have to share it with BNTX. I guess that explains his $70 price target. I think I got his major points right. $Pfizer(PFE)$
精彩评论